Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taro Pharmaceutical Industries Ltd.

www.taro.com

Latest From Taro Pharmaceutical Industries Ltd.

Biogen’s Fampyra Is Felled In Canada

More than a dozen claims in a Canadian patent shielding Biogen’s Fampyra treatment for multiple sclerosis have been cut following challenges launched by two generics firms.

Intellectual Property Legal Issues

Sandoz Deal In Price-Fixing Case Is Largest Ever For Domestic Antitrust Case

$195m deferred prosecution agreement with the US DOJ could be followed by civil settlement that's almost as large, illustrating the strong evidence in the generic price-fixing investigation thus far.

Compliance Legal Issues

OTC Decisions In February: 2 Switches, Label Changes For Excedrin, FeverAll, Naproxen From Biopharma

FDA approved two switches on one day in February, diclofenac gel and olopatadine ophthalmic drops, and stayed busy on OTCs through the month with label changes for Excedrin Migraine packaged with 2-count pouches and for Taro's FeverAll suppositories, and an NDA approval for Biopharma's naproxen.

OTC Drugs Approvals

Sun Sees Urgency To Establish Low Dose Absorica In US

Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.

Commercial Sales & Earnings
See All

Company Information

UsernamePublicRestriction

Register